Cumberland pharmaceuticals inc. announces new publication in infectious diseases and therapy

Cumberland pharmaceuticals inc. announced a new publication in infectious diseases and therapy, showing numerically superior cure rates of telavancin compared to vancomycin within a subset of patients who were enrolled in phase 3 attain trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. cumberland manufactures and distributes telavancin under the brand name vibativ®. vibativ® (telavancin) is a patented, fda approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia. it is also approved for complicated skin and skin structure infections. it addresses a range of gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. hospital-acquired pneumonia and ventilator-associated pneumonia (hap/vap) occur in 5 to >20 cases per 1,000 hospital admissions and 2-16 episodes per 1,000 ventilator days, respectively. alternative treatment options are needed for hap/vap patients with s. aureus infections that test with high vancomycin minimum inhibitory concentration (mic) and patients unable to tolerate vancomycin or linezolid.
CPIX Ratings Summary
CPIX Quant Ranking